People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level
Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level <7% and were more likely to see weight loss of ≥5% vs those who were switched to tirzepatide 2.5 mg or 5 mg with allowed titration up to 15 mg1 This retrospective claims...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.